Treatment with a selective oestrogen receptor modulator

Deep vein thrombosis - Treatment with a selective oestrogen receptor modulator Factor

Last reviewed for CCPS 22 December 2008.

Preliminary questions [25635]

40401 there is some evidence that being treated with a selective oestrogen receptor modulator may be a factor in the development of the condition under consideration.

40402 the veteran has been treated with a selective oestrogen receptor modulator at some time.

25113 the veteran was treated with a selective oestrogen receptor modulator within the 90 days before the clinical onset of the condition under consideration.

25994

the veteran was treated with a selective oestrogen receptor modulator within the 90 days before the clinical onset of the condition under consideration for an illness or injury which is identifiable.

26014 — the veteran has established the causal connection between being treated with a selective oestrogen receptor modulator and VEA service for the clinical onset of deep vein thrombosis.

26015 — the veteran has established the causal connection between being treated with a selective oestrogen receptor modulator and operational service for the clinical onset of deep vein thrombosis.

or

26016 — the veteran has established the causal connection between being treated with a selective oestrogen receptor modulator and eligible service for the clinical onset of deep vein thrombosis.

Clinical onset and operational service [26015]

40403 — the identified illness or injury, for which the veteran was being treated with a selective oestrogen receptor modulator, is causally related to operational service.

Clinical onset and eligible service [26016]

40404 — the identified illness or injury, for which the veteran was being treated with a selective oestrogen receptor modulator, is causally related to eligible service.